Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 12.10.2026 2 Aliment Pharmacol Ther 3 Am J Gastroenterol 4 Clin Gastroenterol Hepatol 1 Dig Dis Sci 2 Gastroenterol Hepatol 1 Gastroenterology 6 Inflamm Bowel Dis 1 J Clin Gastroenterol 3 J Crohns Colitis 1 Lancet Gastroenterol Hepatol 1 Minerva Gastroenterol (Torino) 4 N Engl J Med 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. SUBHAHARAN D, Subramanian S
   Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease-Mechanism-Based Positioning and Emerging Therapeutic Strategies.
   Aliment Pharmacol Ther. 2026 Oct 2. doi: 10.1111/apt.70978.
   PubMed         Abstract available
   
   
2. DEAN R, Yazdanfar M, Zepeda J, Patel IJ, et al
   Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis.
   Aliment Pharmacol Ther. 2026;64:1288-1297.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

3. FAYE AS, Kochar B, Axelrad J, Sun J, et al
   Early Colectomy and Long-Term Risk of Cardiometabolic Disease in Ulcerative Colitis: A Nationwide Cohort Study.
   Am J Gastroenterol. 2026 Oct 6. doi: 10.14309/ajg.0000000000004222.
   PubMed         Abstract available
   
   
4. GONZALEZ MM, Ahuja D, Qi Y, Xu R, et al
   Evolving Treatment Patterns and Clinical Outcomes in Children with Newly Diagnosed Crohn's Disease and Ulcerative Colitis in the United States, 2007-2023.
   Am J Gastroenterol. 2026 Oct 6. doi: 10.14309/ajg.0000000000004219.
   PubMed         Abstract available
   
   
5. GULATI AS
   How I Approach It: Ustekinumab for Pediatric Crohn's Disease.
   Am J Gastroenterol. 2026 Oct 6. doi: 10.14309/ajg.0000000000004223.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

6. OLIVERA PA, Lasa JS, Singh S, Jairath V, et al
   EFFICACY AND SAFETY OF ADVANCED THERAPIES AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.
   Clin Gastroenterol Hepatol. 2026 Oct 6:S1542-3565(26)00742.
   PubMed         Abstract available
   
   
7. GILMORE R, Fernandes R, Goetz N, Chin S, et al
   Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage therapy.
   Clin Gastroenterol Hepatol. 2026 Oct 6:S1542-3565(26)00752.
   PubMed         Abstract available
   
   
8. UKASHI O, Kopylov U, Ungar B, Asher AT, et al
   Induction of mucosal healing by biologics is topographically comparable in proximal and distal small bowel Crohn's disease.
   Clin Gastroenterol Hepatol. 2026 Oct 5:S1542-3565(26)00748.
   PubMed         Abstract available
   
   
9. SINGH S, Nardone OM, Allocca M, Yuan Y, et al
   TREAT-TO-TARGET IN INFLAMMATORY BOWEL DISEASE: PROMISE, PERILS, AND THE PATH FORWARD.
   Clin Gastroenterol Hepatol. 2026 Oct 3:S1542-3565(26)00736.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

10. CHIN S, Cao R, Demase K, Nguyen A, et al
    Reflecting on Quality-of-Care Delivery in Inflammatory Bowel Disease Pregnancy: The (Pause and Reflect) PAUSA Study.
    Dig Dis Sci. 2026 Oct 7. doi: 10.1007/s10620-026-10246.
    PubMed         Abstract available
    
    

    
    Gastroenterol Hepatol

11. CUADRO CP, Garcia-Lopez S, Esteban AR, Francisco R, et al
    Distinct Microbiological Profile of Intra-Abdominal Abscesses in Crohn's Disease: A Multicenter Cohort Study from GETECCU.
    Gastroenterol Hepatol. 2026 Oct 9:502893. doi: 10.1016/j.gastrohep.2026.502893.
    PubMed         Abstract available
    
    
12. FERNANDO MUNOZ J, Gutierrez-Casbas A, Rodriguez C, Gisbert JP, et al
    EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-alpha as first- and second-line biologic treatment in Crohn's disease.
    Gastroenterol Hepatol. 2026 Oct 7:502871. doi: 10.1016/j.gastrohep.2026.502871.
    PubMed         Abstract available
    
    

    
    Gastroenterology

13. CUSHING-DAMM KC, Yin L, Chen Y, Oliveri A, et al
    HLA-DRB1*01:03 is a Reproducible Biomarker of Colectomy Risk in Ulcerative Colitis.
    Gastroenterology. 2026 Oct 8:S0016-5085(26)07324.
    PubMed        
    
    

    
    Inflamm Bowel Dis

14. CHIN S, Demase K, Corte C, Wong D, et al
    Readability and quality of online inflammatory bowel disease pregnancy resources: authors' reply.
    Inflamm Bowel Dis. 2026 Oct 5:izag152. doi: 10.1093.
    PubMed        
    
    
15. HONG S, Kim KW, Im Y, Jang J, et al
    Enterotype-based stratification identifies clinically distinct microbial subtypes in inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Oct 5:izag176. doi: 10.1093.
    PubMed         Abstract available
    
    
16. SUBHAHARAN D, Mohsen W, Kakkadasam Ramaswamy P
    Infliximab intensification in acute severe ulcerative colitis: The next question is patient selection.
    Inflamm Bowel Dis. 2026 Oct 7:izag206. doi: 10.1093.
    PubMed        
    
    
17. KAKIUCHI T
    Current evidence for first-line advanced therapies in pediatric ulcerative colitis: a critical review.
    Inflamm Bowel Dis. 2026 Oct 8:izag203. doi: 10.1093.
    PubMed         Abstract available
    
    
18. DALSGARETH SP, Pkb KKB, Seidelin JB, Bjerrum JT, et al
    Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis.
    Inflamm Bowel Dis. 2026 Oct 8:izag177. doi: 10.1093.
    PubMed         Abstract available
    
    
19. WANCHAITANAWONG W, Limsrivilai J
    Response to "Isolated perianal Crohn's disease: the next challenge is long-term surveillance".
    Inflamm Bowel Dis. 2026 Oct 9:izag207. doi: 10.1093.
    PubMed        
    
    

    
    J Clin Gastroenterol

20. FELDMAN HT, Tejan J, Victoria R, Rupawala A, et al
    Wearable Technology and Remote Physiological Monitoring in Inflammatory Bowel Disease: Erratum.
    J Clin Gastroenterol. 2026;60:946.
    PubMed        
    
    

    
    J Crohns Colitis

21. SUBHAHARAN D, Mohsen W, Shahzad A, Patrick D, et al
    Contemporary multicentre validation and comparative performance of Day 1 prognostic scores in acute severe ulcerative colitis.
    J Crohns Colitis. 2026;20:jjag155.
    PubMed         Abstract available
    
    
22. BARENDREGT DMH, Tuk B, Hulleman-van Haaften DH, Camman AE, et al
    Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease course.
    J Crohns Colitis. 2026;20:jjag146.
    PubMed         Abstract available
    
    
23. SHEHAB M, Azzam N, Al-Hindawi A, Alrashed F, et al
    Epidemiology of inflammatory bowel disease in the Middle East and North Africa: a multinational, tertiary care registry (MIRAGE) study.
    J Crohns Colitis. 2026;20:jjag145.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

24. HONAP S, Dignass A, Jairath V, Danese S, et al
    Defining molecular remission in inflammatory bowel disease: lessons from oncology.
    Lancet Gastroenterol Hepatol. 2026;11:944-946.
    PubMed        
    
    

    
    Minerva Gastroenterol (Torino)

25. PEZZELLA C, Locorotondo L, Chiera E, DI Vincenzo F, et al
    Beyond Crohn's disease: ileal Kaposi sarcoma in a transplant recipient presenting with subocclusive symptoms. A concomitant diagnosis of Crohn's disease and ileal Kaposi sarcoma.
    Minerva Gastroenterol (Torino). 2026 Oct 7. doi: 10.23736/S2724-5985.26.04227.
    PubMed         Abstract available
    
    

    
    N Engl J Med

26. ANTONIOLI L
    Interleukin-10 Autoantibodies in Inflammatory Bowel Disease.
    N Engl J Med. 2026;395:1457-1458.
    PubMed        
    
    
27. KUCUK H, Erden A, Tufan A
    Interleukin-10 Autoantibodies in Inflammatory Bowel Disease.
    N Engl J Med. 2026;395:1458.
    PubMed        
    
    
28. BAI X, Xu C, Yang H
    Interleukin-10 Autoantibodies in Inflammatory Bowel Disease.
    N Engl J Med. 2026;395:1458-1459.
    PubMed        
    
    
29. UHLIG HH, Hambleton S, Travis S
    Interleukin-10 Autoantibodies in Inflammatory Bowel Disease. Reply.
    N Engl J Med. 2026;395:1459.
    PubMed        
    
    

    
    PLoS One

30. PAN H, Zhai L, Zhao S, Guo Z, et al
    Impaired fatty acid oxidation and mitochondrial injury mediated by the AMPK/PPARalpha pathway: A key mechanism in high-fat diet-aggravated ulcerative colitis.
    PLoS One. 2026;21:e0358354.
    PubMed         Abstract available
    
    
31. CHEN YT, Wang ZC, Liu HM, Zhao CZ, et al
    The burden of inflammatory bowel disease in Asia (1990-2023) and projections to 2050: A comprehensive analysis of the 2023 global burden of disease study.
    PLoS One. 2026;21:e0359856.
    PubMed         Abstract available
    
    
32. DEMERS K, van Kuijk SMJ, Pierik MJ, Jonkers DMAE, et al
    Prediction of oxygen uptake at peak exercise in patients with inflammatory bowel disease using submaximal cardiopulmonary exercise testing and the steep ramp test as a practical field test.
    PLoS One. 2026;21:e0354707.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum